Shire plc: PharmaVitae Report

Introduction

This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs

Features and benefits

* Gain insight into Shire's strategic outlook across the next 6 years
* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Shire's performance through to 2016 will be shaped by the decline in sales of its biggest drug, Adderall XR, due to generic erosion. However, this will be counteracted by gains associated with uptake of its new ADHD offerings Vyvanse and Intuniv in recently expanded indications.

Your key questions answered

* Benchmark Shire's performance against key rivals in the prescription pharmaceutical sector
* Assess how successful Shire will be in diversifying its business focus and reducing its reliance on the US ADHD market
* See how Shire has developed a portfolio of products indicated for highly symptomatic diseases in an effort to build sustainable growth
[Studien Infos ausblenden]

Executive Summary
Key findings
Shire prescription pharma sales outlook
Shire financial outlook
Key developments
[Missing title]
Upcoming developments
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Strategic Insight
Company Introduction
Sales Analysis
Financial Analysis
Product Analysis
Data sourcing
Analyst consensus
STRATEGIC INSIGHT
Key findings
Strategic insight
Shire’s lifecycle management drove ADHD franchise growth
A diversified business with a common theme
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Acquisition of Imperial Pharmaceutical Services
Acquisition of Pharmavene
Acquisition of Richwood
Merger with Roberts Pharmaceutical Corporation
Acquisition of Fuisz Technologies’ EU subsidiaries
Acquisition of BioChem Pharma
Acquisition of Atlantic Pharmaceutical
Divestment of OTC products
Divestment of vaccines business
Acquisition of Transkaryotic Therapies
Acquisition of New River Pharmaceuticals
Divestment of non-core products
Acquisition of Jerini
Acquisition of Movetis
Acquisition of Advanced BioHealing
Current corporate structure
Specialty Pharmaceuticals
Human Genetic Therapies
SALES ANALYSIS
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2004–16
Product analysis
Product analysis, 2004–10
Product analysis, 2010–16
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Launch analysis, 2010–16
Core analysis, 2010–16
Expiry analysis, 2010–16
Generics analysis, 2010–16
Launch/core/expiry configuration, 2010–16
Molecule type analysis
Externalization analysis
FINANCIAL ANALYSIS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2004–10
Operating costs and profit analysis
Operating costs and profit analysis, 2004–10
Operating cost ratio and profit margin analysis, 2004–10
Operating cost ratio and profit margin analysis, 2010–16
Operating costs and profit analysis, 2010–16
PRODUCT ANALYSIS
Overview
Vyvanse
Replagal
Lialda / Mezavant
Adderall XR
Elaprase
Vpriv
Intuniv
Resolor
Shire pipeline overview
APPENDIX
References
Abbreviations
Exchange rates
[Inhaltsverzeichnis ausblenden]